Unexpected cytokines in serum of malignant melanoma patients during sequential biochemotherapy

Clinical Cancer Research

Volumn 6, Issue 10, 2000, Pages 3895-3903

  Grimm, E A ^a   Smid, C M ^a   Lee, J J ^a   Tseng, C H ^a   Eton, O ^a   Buzaid, A C ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; CYTOKINE; DACARBAZINE; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR; INTERLEUKIN 6; NEOPTERIN; NITRIC OXIDE; NITRITE; RECOMBINANT ALPHA2A INTERFERON; RECOMBINANT ALPHA2B INTERFERON; TUMOR NECROSIS FACTOR ALPHA; VINBLASTINE;

ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ARTICLE; CORRELATION FUNCTION; CYTOKINE RELEASE; DRUG RESPONSE; HUMAN; MACROPHAGE ACTIVATION; MELANOMA; PRIORITY JOURNAL; TH2 CELL; TREATMENT OUTCOME; TUMOR REGRESSION;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYCLOPHOSPHAMIDE; CYTOKINES; DACARBAZINE; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; INTERFERON ALFA-2B; INTERLEUKIN-10; INTERLEUKIN-2; INTERLEUKIN-6; INTERLEUKINS; MACROPHAGE ACTIVATION; MACROPHAGES; MELANOMA; NEOPTERIN; NITRITES; RADIOIMMUNOASSAY; RANDOM ALLOCATION; RECEPTORS, INTERLEUKIN-2; TIME FACTORS; TUMOR NECROSIS FACTOR-ALPHA; VINCRISTINE;

EID: 0033765387     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Biochemotherapy in the treatment of advanced melanoma: Clinical results and potential mechanisms of anticancer activity
2. Combination of chemotherapy with interleukin-2 and interferon-α for the treatment of advanced melanoma
3. Biochemotherapy for advanced melanoma
4. Mechanism of the anti-tumor effect of biochemotherapy in melanoma: Preliminary results
5. Systemic treatments for advanced cutaneous melanoma
6. Involvement of soluble and cellular high affinity IL2 receptors in clinical response to chemoimmunotherapy (C1)
7. Is there any relationship between interleukin-6/interleukin-6 receptor modulation and endogenous interleukin-6 release in metastatic malignant melanoma patients treated by biochemotherapy?
8. Nitric oxide and neopterin levels and clinical response in stage III melanoma patients receiving concurrent biochemotherapy
9. Phase II study of neoadjuvant concurrent biochemotherapy in melanoma patients with local-regional metastases
10. DNA damage in peripheral blood mononuclear cells correlates with response to biochemotherapy in melanoma
11. Results of the M.D. Anderson Cancer Center Phase III trial of 'sequential' biochemotherapy using CVD (cisplatin, vinblastine, dacarbazine) with interferon α-2B and interleukin-2 v. CVD alone for patients with metastatic melanoma
12. Tumor-dependent increased plasma nitrate concentrations as an indication of the antitumor effect of flavone-8-acetic acid and analogues in mice
13. Nitrite/nitrate and cytokine levels in bronchoalveolar lavage fluid of lung cancer patients
14. Induction of circulation tumor necrosis factor (TNF α) as the mechanism for the febrile response to interleukin-2 (IL-2) in cancer patients
15. Cytokines: Biology and applications in cancer medicine
16. A polymorphic dinucleotide repeat in the human IL-10 promoter
17. A second polymorphic dinucleotide repeat in the 5' flanking region of the human IL10 gene
18. High-dose recombinant interleukin-2 therapy for patients with metastatic melanoma: Analysis of 270 patients treated between 1985 and 1993
19. Role of recombinant interleukin-2 in combination with interferon-α and chemotherapy in the treatment of advanced melanoma
20. Interleukin-6 production and secretion in human melanoma cell lines: Regulation by interleukin-1
21. Differential increase of Fas ligand expression on metastatic vs thin or thick primary melanoma and comparison to IL-10
22. IL-10 inhibits cytokine production by activated macrophages
23. Interleukin-10
24. Homology of cytokine synthesis inhibitory factor (IL-10) to the Epstein-Barr virus gene BCRFI
25. Interleukin 10 production by human melanoma
26. Localization of IL-10 production in melanoma tissues
27. Increased interleukin-10 serum levels in patients with solid tumours
28. Immunizing and curative potential of replicating and nonreplicating murine mammary adenocarcinoma cells engineered with interleukin (IL)-2, IL-4, IL-6, IL-7, IL-10, tumor necrosis factor α, granulocyte-macrophage colony-stimulating factor, and γ-interferon gene or admixed with conventional adjuvants
29. Local release of IL-10 by transfected mouse mammary adenocarcinoma cells does not suppress but enhances antitumor reaction and elicits a strong cytotoxic lymphocyte and antibody-dependent immune memory
30. Antimetastatic and antitumor activities of interleukin 10 in a murine model of breast cancer
31. Loss of tumorigenicity and increased immunogenicity induced by interleukin-10 gene transfer in B16 melanoma cells
32. Tumor-induced interleukin-10 inhibits type 1 immune responses directed at a tumor antigen as well as a non-tumor antigen present at the tumor site
33. Interleukin-10 is a growth factor for human melanoma cells and down-regulates HLA class-I, HLA class-II and ICAM-1 molecules
34. IL-10 gene transfer to intracranial 9L glioma: Tumor inhibition and cooperation with IL-2
35. Interleukin-10 gene transfer inhibits murine mammary tumors and elevates nitric oxide
36. Interleukin-10 inhibits tumor metastasis, downregulates MHC class I, and enhances NK lysis
37. Interleukin 10 suppresses tumor growth and metastasis of human melanoma cells: Potential inhibition of angiogenesis
38. Interleukin-10 gene transfer activates interferon-γ and the interferon-γ-inducible genes Gbp-1/Mag-1 and Mig-1 in mammary tumors
39. Systemic administration of cellular IL-10 induces an effective, specific, and long-lived immune response against established tumors in mice
40. Properties of IL-2 activated lymphocytes
41. Treatment of metastatic melanoma with combined chemotherapy containing cisplatin, vinblastine and dacabazine (CVD) and biotherapy using interleukin-2 and interferon-α